Could IL-17A be a novel therapeutic target in diabetic nephropathy?
Rayego Mateos, Sandra
Opazo Rios, Lucas
Marquez Exposito, Laura
Tejera Muñoz, Antonio
Navarro González, Juan F.
MetadataShow full item record
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy.
Is part ofJournal of clinical medicine, 2020, vol. 9, núm. 1, p.1-17
European research projects
The following license files are associated with this item: